Wells Fargo Raises Amgen Price Target to $435 Amid Mixed Signals

Amgen's price target was raised by Wells Fargo to $435 from $400, reflecting an 8.75% increase, while maintaining its Equal-Weight rating on the biotechnology firm.

The adjustment comes as a series of other positive rating updates from various analysts suggest Amgen is on a solid path.

Amgen's GF Value℠ is calculated at $365.65, indicating that the stock is currently trading at a 19.5% premium to its intrinsic value, suggesting limited margin for safety for new investors considering an entry point.

The company's strong fundamentals and profitability are evident in its high GF Score℠ of 79/100, but its momentum rank remains low at 1/10, suggesting the stock may not be currently favored by the market.